Just days before a Dec. 31 deadline, the U.K. and the European Union have agreed to terms on a historic Brexit deal that establishes a framework for how .
Share:
BioNTech SE (NASDAQ: BNTX) the German partner of
Pfizer Inc (NYSE: PFE) expressed confidence that two companies’ jointly-developed vaccine is effective against a new mutation of COVID-19, Reuters reported Monday.
What Happened: Sahin told Germany’s Bild TV that BioNTech would look into the mutation that has emerged out of the United Kingdom in the coming days and viewed the matter “with a degree of soberness,” as per Reuters.
The executive also disclosed he had not yet been vaccinated and said it was more important for the employees to get the vaccine so they can perform their jobs.
Why It Matters: Sahin’s comments on the new COVID-19 strain come after the World Health Organization also lent its voice against alarmism surrounding the mutation, noted Reuters.